Foghorn Therapeutics to Participate at the 2021 Jefferies London Healthcare Conference

Rhea-AI Summary

Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company, will virtually participate in the 2021 Jefferies London Healthcare Conference. The event includes a presentation and investor 1x1 meetings, available on-demand from November 18, 2021, 8:00am GMT to November 19, 2021, 5:00pm GMT. Foghorn specializes in developing medicines that target the chromatin regulatory system and is advancing multiple oncology product candidates. For more details and the presentation access, visit www.foghorntx.com.

CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, today announced that Foghorn management will participate virtually at the 2021 Jefferies London Healthcare Conference.

2021 Jefferies London Healthcare Conference
Format: Virtual presentation and investor 1x1 meetings
The presentation will be available on-demand starting Thursday, November 18, 2021, at 8:00am GMT / 3:00am ET through Friday, November 19, 2021, at 5:00pm GMT / 12:00pm ET.

Please find a link to the presentation here.

A webcast can also be accessed under “Events & Presentations” in the Investors section of the Company’s website, www.foghorntx.com

About Foghorn Therapeutics

Foghorn^® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control^® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The company is developing multiple product candidates in oncology.

Media Contact:

Fanny Cavalié, Foghorn Therapeutics Inc.
fcavalie@foghorntx.com

Gregory Kelley, Ogilvy
gregory.kelley@ogilvy.com

Investor Relations Contact:

Ben Strain, Foghorn Therapeutics Inc.
bstrain@foghorntx.com

Hans Vitzthum, LifeSci Advisors
617-430-7578
hans@lifesciadvisors.com

FAQ

What is the date of the 2021 Jefferies London Healthcare Conference for FHTX?

Foghorn Therapeutics will participate in the conference from November 18, 2021, at 8:00am GMT to November 19, 2021, at 5:00pm GMT.

How can I access the FHTX presentation at the Jefferies London Healthcare Conference?

The FHTX presentation will be available on-demand starting November 18, 2021, and can be accessed through their website or directly at the conference link.

What type of company is Foghorn Therapeutics (FHTX)?

Foghorn Therapeutics is a clinical stage biotechnology company focusing on developing medicines that modulate gene expression by targeting the chromatin regulatory system.

Where can I find more information about Foghorn Therapeutics?

For more information, visit Foghorn Therapeutics' official website at www.foghorntx.com.